Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era

Kenrick Ng; Krishna Vinnakota; Anand Sharma; John Kelly; Prokar Dasgupta; Nikhil Vasdev

doi:10.1038/s41585-020-00419-z

Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era

Nat Rev Urol. 2021 Apr;18(4):185-187. doi: 10.1038/s41585-020-00419-z.

Authors

Kenrick Ng¹, Krishna Vinnakota², Anand Sharma³, John Kelly⁴, Prokar Dasgupta⁵, Nikhil Vasdev^{6

7}

Affiliations

¹ Department of Medical Oncology, UCL Cancer Institute, University College London, London, UK.
² Department of Medicine, King's College Hospital NHS Trust, London, UK.
³ Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
⁴ Division of Surgery and Interventional Science, University College London, London, UK.
⁵ Faculty of Life Sciences and Medicine, King's College London, London, UK.
⁶ Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Stevenage, UK. nikhilvasdev@doctors.org.uk.
⁷ School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. nikhilvasdev@doctors.org.uk.

Abstract

The COVID-19 pandemic has resulted in a substantial increase in waiting times for cystoscopies, prompting concerns of delayed diagnoses and substandard surveillance of bladder cancer. Expanding the role of urinary biomarkers in diagnostic and surveillance pathways could be a strategy to address this problem, and several novel biomarkers have shown promise for this purpose.

Publication types

Review

MeSH terms

Biomarkers, Tumor / urine*
COVID-19 / epidemiology*
COVID-19 / prevention & control
Delayed Diagnosis / prevention & control
Delayed Diagnosis / trends*
Humans
Randomized Controlled Trials as Topic / methods
Urinary Bladder Neoplasms / diagnosis
Urinary Bladder Neoplasms / epidemiology*
Urinary Bladder Neoplasms / urine*

Substances

Biomarkers, Tumor